Send to

Choose Destination
Gynecol Oncol Rep. 2016 Dec 14;19:10-12. doi: 10.1016/j.gore.2016.12.003. eCollection 2017 Feb.

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1).

Author information

Department of Obstetrics & Gynecology & Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, United States.
Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, United States.



The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed.


We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC overexpressing HER2/neu at 3 + level by IHC treated with the anti-HER2/neu antibody-drug-conjugate (ADC) trastuzumab-emtansine (TDM-1-Kadcyla-Genentech/Roche). She experienced a remarkable clinical response to TDM-1 with a complete resolution of a large metastatic, radiation/chemotherapy resistant tumor deposit in her abdominal wall muscle confirmed by multiple CAT scans and a prolonged systemic control of her disease.


TDM-1 may represent a novel treatment option for recurrent/metastatic HER2/neu-positive USC patients refractory to salvage-treatment.


HER2/neu; Trastuzumab-emtansine; Uterine serous carcinoma

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center